Journal list menu
IssueCancer Communications: Volume 41, Issue 2
89-196February 2021
Export Citations
Download PDFs
ISSUE INFORMATION
REVIEWS
Tumor heterogeneity and the potential role of liquid biopsy in bladder cancer
- Pages: 91-108
- First Published: 30 December 2020
LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer
- Pages: 109-120
- First Published: 29 October 2020
ORIGINAL ARTICLES
CRISPR/Cas9 screening identifies a kinetochore-microtubule dependent mechanism for Aurora-A inhibitor resistance in breast cancer
- Pages: 121-139
- First Published: 20 January 2021
These findings provide a potential combinational drug target for promoting the therapeutic effects of MLN8237 and reveal a relationship between centromere-related functions and the sensitivity of Aurora-A inhibitor.
Dicer-independent snRNA/snoRNA-derived nuclear RNA 3 regulates tumor-associated macrophage function by epigenetically repressing inducible nitric oxide synthase transcription
- Pages: 140-153
- First Published: 17 January 2021
Nuclear small RNAs conducting gene-specific epigenetic regulation have not been clearly identified in adult mammals. Through establishing cytoplasmic and nuclear small RNomes in innate immune cells, we revealed that sdnRNA-3, one of the new class of nucleus-localized and dicer-independent small RNAs derived from snRNAs/snoRNAs, inhibited transcription of Nos2 gene (encode iNOS) by decreasing chromatin accessibility of gene promoter in macrophages, increasing the tumor promoting function of tumor-associated macrophages.
S100A8 promotes epithelial-mesenchymal transition and metastasis under TGF-β/USF2 axis in colorectal cancer
- Pages: 154-170
- First Published: 03 January 2021
In colorectal cancer, S100A8 in tumor cells predicts poor prognosis but that in stroma cells indicates good prognosis. We first proved that TGF-β promotes metastasis through upregulated intracellular USF2/S100A8 axis, and USF2 maybe is the switcher on the opposite function of intracellular and extracellular S100A8.
Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study
- Pages: 171-182
- First Published: 02 February 2021
BAT8001 demonstrated favorable safety and tolerability profiles, with promising anti-tumour activity in patients with HER2-positive advanced or recurrent solid tumours. BAT8001 has the potential to provide a new therapeutic option in heavily pretreated patients with metastatic Her2-positive breast cancer.
LETTERS TO THE EDITOR
Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors
- Pages: 183-186
- First Published: 12 January 2021
RNF114 suppresses metastasis through regulation of PARP10 in cervical cancer cells
- Pages: 187-191
- First Published: 08 January 2021
High-throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion
- Pages: 192-196
- First Published: 16 January 2021
Sign up for email alerts
Tools
More from this journal
Cancer collection based on different tumor types
Information for Authors
Cancer Communications offers waivers to authors for selected high quality articles. For rapid feedback on the potential suitability of an article for waiver, please send a pre-submission enquiry to the editorial office, providing the article title, abstract and a brief cover letter.
Impact Factors in Journal Citation Report (2018, Clarivate) are under the previous journal title Chinese Journal of Cancer.
Archival Content
To browse articles published in the journal prior to March 2015, please visit the Sun Yat-sen University Cancer Center website.
Understanding Open Access
As an open access journal, all articles in Cancer Communications are freely available to read, download and share immediately on publication.
Relevant Open – Access Health Sciences journals
Aging AND Cancer (2020-Present)
Cancer Innovation (2022-Present)
Clinical and Translational Medicine (2012-Present)
MedComm (2020-Present)
MedComm – Oncology (2022-Present)